Iterum Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2021 Financial Results on March 28, 2022
March 21 2022 - 8:00AM
Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a
clinical-stage pharmaceutical company focused on developing next
generation oral and IV antibiotics to treat infections caused by
multi-drug resistant pathogens in both community and hospital
settings, today announced that the Company will release its
fourth quarter and full year 2021 financial results before the open
of the U.S. financial markets on Monday, March 28,
2022. Management will host a conference call at 8:30 a.m.
ET that day to discuss the Company’s financial results and
provide an update on its business.
To access the call please dial 844-200-6205
(domestic) or 929-526-1599 (international) and refer to Access Code
096194. The audio webcast can be accessed under “Financials &
Filings” in the Investors section of the Company’s website at
www.iterumtx.com following the call.
About Iterum Therapeutics
plc
Iterum Therapeutics plc is a clinical-stage pharmaceutical
company dedicated to developing differentiated anti-infectives
aimed at combatting the global crisis of multi-drug resistant
pathogens to significantly improve the lives of people affected by
serious and life-threatening diseases around the world. Iterum is
currently advancing its first compound, sulopenem, a novel penem
anti-infective compound, in Phase 3 clinical development with an
oral formulation. Sulopenem also has an IV formulation. Sulopenem
has demonstrated potent in vitro activity against a wide variety of
gram-negative, gram-positive and anaerobic bacteria resistant to
other antibiotics. Iterum has received Qualified Infectious Disease
Product (QIDP) and Fast Track designations for its oral and IV
formulations of sulopenem in seven indications. For more
information, please visit http://www.iterumtx.com.
Forward-Looking Statements
This press release contains forward-looking
statements. These forward-looking statements include, without
limitation, statements regarding the development, therapeutic and
market potential of sulopenem. In some cases, forward-looking
statements can be identified by words such as “may,” “believes,”
“intends,” “seeks,” “anticipates,” “plans,” “estimates,” “expects,”
“should,” “assumes,” “continues,” “could,” “would,” “will,”
“future,” “potential” or the negative of these or similar terms and
phrases. Forward-looking statements involve known and unknown
risks, uncertainties and other factors that may cause Iterum’s
actual results, performance or achievements to be materially
different from any future results, performance or achievements
expressed or implied by the forward-looking statements.
Forward-looking statements include all matters that are not
historical facts. Actual future results may be materially different
from what is expected due to factors largely outside Iterum’s
control, including uncertainties inherent in the initiation and
conduct of clinical and non-clinical development, including any
potential additional clinical trials and non-clinical development
that may be conducted in response to the complete response letter
received by Iterum in July 2021, availability and timing of data
from such potential clinical and non-clinical development, changes
in regulatory requirements or decisions of regulatory authorities,
the timing or likelihood of regulatory filings and approvals,
including any potential resubmission of the new drug application
for oral sulopenem, changes in public policy or legislation,
commercialization plans and timelines, if oral sulopenem is
approved, the actions of third-party clinical research
organizations, suppliers and manufacturers, the accuracy of
Iterum’s expectations regarding how far into the future Iterum’s
cash on hand will fund Iterum’s ongoing operations including
completing potential additional clinical and non-clinical
development of oral sulopenem, the impact of COVID-19 and related
responsive measures thereto, Iterum’s ability to maintain its
listing on the Nasdaq Stock Market, risks and uncertainties
concerning the outcome, impact, effects and results of Iterum’s
evaluation of corporate, strategic, financial and financing
alternatives, including the terms, timing, structure, value,
benefits and costs of any corporate, strategic, financial or
financing alternative and Iterum’s ability to complete one at all
and other factors discussed under the caption “Risk Factors” in its
Quarterly Report on Form 10-Q filed with the Securities and
Exchange Commission (the “SEC”) on November 12, 2021, and other
documents filed with the SEC from time to time. Forward-looking
statements represent Iterum’s beliefs and assumptions only as of
the date of this press release. Except as required by law, Iterum
assumes no obligation to update these forward-looking statements
publicly, or to update the reasons actual results could differ
materially from those anticipated in the forward-looking
statements, even if new information becomes available in the
future.
Investor Contact:Judy
MatthewsChief Financial Officer
312-778-6073IR@iterumtx.com
Iterum Therapeutics (NASDAQ:ITRM)
Historical Stock Chart
From Aug 2024 to Sep 2024
Iterum Therapeutics (NASDAQ:ITRM)
Historical Stock Chart
From Sep 2023 to Sep 2024